Table 1.
Genomic imprinting and DNA methylation of IGF2 in selected human cell lines
| Cell lines | IGF2 imprinting | DNA methylation |
Nuclear transfer | |
|---|---|---|---|---|
| ICR | DMR0 | |||
| WTCL (Wilms' tumor) | LOI | +/− | −/− | Nuclear donor |
| SKNEP (Wilms' tumor) | LOI | +/− | −/− | Nuclear donor |
| H522 (lung cancer) | LOI | −/− | −/− | Nuclear donor |
| HRT18 (colorectal cancer) | LOI | +/− | +/+ | Nuclear donor |
| HBF1 (human fibroblast) | MOI | +/− | +/− | Acceptor |
| MBW2 (mouse fibroblast) | MOI | +/− | +/− | Acceptor |
| ASPC cells (pancreatic cancer) | MOI | +/− | −/− | CHX-treated |
| LOI: loss of IGF2 imprinting (bi-allelic expression). | ||||
| MOI: maintenance of IGF2 imprinting (mono-allelic expression). | ||||
| +/−: two parental alleles were differentially methylated. | ||||
| +/+: two parental alleles were fully methylated. | ||||
| −/−: two parental alleles were unmethylated. | ||||
| CHX: cycloheximide. | ||||